Melanotan (Afamelanotide)

[Guide]

Melanotan II is a synthetic analog of the naturally occurring peptide hormone alpha-melanocyte stimulating hormone (α-MSH) that has been shown to have tanning and aphrodisiac properties in preliminary studies and clinical trials. It is a cyclic lactam analog of α-MSH with the amino acid sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2.

"Afamelanotide, originally developed under the names "Melanotan 1" or "Melanotan I" for skin tanning, a drug currently in trials in implant form as a prophylactic treatment for a series of light affected skin is also included in this report. As of 2009 no compound incorporating the melanotan II peptide has ever been approved for use by any governmental drug regulatory bodies outside of clinical trials. Unlicensed and untested powders sold as "melanotan II" are found on the Internet however, multiple regulatory bodies have warned consumers they may be unsafe and ineffective." [1]

However, the Italian government in 2010 has approved Afamelanotide (melanotan) according to this report by David Pascoe.

Some rosaceans report in the various rosacea online support groups they are using it, however, you can no longer read about it (by clicking here in the rosacea archive). 

Scenesse (INN: afamelanotide) is Clinuvel's proprietary first-in-class photoprotective drug, currently in Phase II and III clinical trials. The link More info about this is not longer available. 

Melanotan II
"It was under development as drug candidate for female sexual dysfunction and erectile dysfunction but clinical development ceased by 2003, and as of 2018, no product containing melanotan II was marketed and all commercial development had ceased.[1] Unlicensed, untested, or fraudulent products sold as "melanotan II" are found on the Internet, and purported to be effective as "tanning drugs", though side effects such as uneven pigmentation, new nevi (moles), and darkening or enlargement of existing moles are common and have led to medical authorities discouraging use." [1]

End Notes

[1] Wikipedia

More info